Can elevated levels of Interleukin-1 beta (IL-1β) and Interleukin-18 (IL-18) indicate activation of NLRP3 (Nucleotide-binding domain, leucine-rich repeat-containing family, pyrin domain-containing 3)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Elevated levels of Interleukin-1 beta (IL-1β) and Interleukin-18 (IL-18) can indicate activation of NLRP3 (Nucleotide-binding domain, leucine-rich repeat-containing family, pyrin domain-containing 3), as these cytokines are produced by inflammasome activation, which is a key component of the NLRP3 pathway 1.

Key Points

  • IL-18 is a proinflammatory cytokine produced by inflammasome activation, which drives IFNγ overproduction 1.
  • NLRP3 activation leads to the production of IL-1β and IL-18, which are key players in the inflammatory response 1.
  • Elevated levels of IL-18 have been associated with macrophage activation syndrome (MAS), a life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD) 1.
  • The measurement of IL-18 and other biomarkers, such as S100 proteins, can be useful in the diagnosis and management of sJIA and AOSD 1.

Biomarker Levels

  • Elevated levels of IL-18 (>68,363 ng/mL) have been reported in patients with sJIA-MAS compared to those with active sJIA without MAS 1.
  • IL-18 levels have also been shown to distinguish MAS from active sJIA with high sensitivity and specificity 1.
  • The measurement of IL-18 and other biomarkers, such as CXCL9 and ADA2 activity, can be useful in the diagnosis and management of MAS 1.

From the Research

NLRP3 Inflammasome Activation

  • Elevated levels of Interleukin-1 beta (IL-1β) and Interleukin-18 (IL-18) can indicate activation of NLRP3 inflammasome, as these cytokines are produced upon activation of the NLRP3 inflammasome 2, 3, 4.
  • The NLRP3 inflammasome is a multiprotein complex that activates caspase-1, leading to the maturation of IL-1β and IL-18, and the induction of pyroptosis, a form of cell death 2.
  • The activation of NLRP3 inflammasome can be triggered by diverse stimuli, including reactive oxygen species, lysosomal rupture, or cytosolic ion perturbation 5, 4.

IL-1β and IL-18 Production

  • IL-1β and IL-18 have both shared and unique biological functions, with IL-1β being an important mediator of the acute phase response to infections and tissue damage, and IL-18 taking part in activation and tailoring of the adaptive immune response 3.
  • The ratio of IL-1β to IL-18 production can vary depending on the stimulus used to activate the NLRP3 inflammasome, with some stimuli inducing a higher ratio of IL-1β to IL-18 production 3.
  • The production of IL-1β and IL-18 is strictly dependent on a functional NLRP3 inflammasome, and the differences in their production do not depend on the level of gene expression, caspase-1 activity, or pyroptosis 3.

Regulation of NLRP3 Inflammasome

  • The NLRP3 inflammasome is regulated by various metabolic pathways, which converge to modulate its activation 4.
  • Micro-ribonucleic acid (RNA)-223 (miR-223) has been shown to regulate the NLRP3-inflammasome activation, and its expression is altered in patients with severe COVID-19 6.
  • The dysregulation of NLRP3 inflammasome followed by IL-1β production has been implicated in the pathogenesis of various inflammatory diseases, including COVID-19 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.